James D Brooks1, Wei Wei2, Jonathan R Pollack3, Robert B West3, Jun Ho Shin4, John B Sunwoo4, Sarah J Hawley5, Heidi Auman5, Lisa F Newcomb6, Jeff Simko7, Antonio Hurtado-Coll8, Dean A Troyer9,10, Peter R Carroll11, Martin E Gleave8, Daniel W Lin6, Peter S Nelson12, Ian M Thompson13, Lawrence D True14, Jesse K McKenney15, Ziding Feng2, Ladan Fazli8. 1. Department of Urology, Stanford University, Stanford, California. jdbrooks@stanford.edu. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Pathology, Stanford University, Stanford, California. 4. Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, California. 5. Canary Foundation, Canary Center at Stanford, Palo Alto, California. 6. Department of Urology, University of Washington Medical Center, Seattle, Washington. 7. Department of Pathology, University of California San Francisco, San Francisco, California. 8. Department of Urologic Sciences and Vancouver Prostate Centre, Vancouver, British Columbia, Canada. 9. Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 10. Eastern Virginia Medical School, Pathology and Microbiology and Molecular Biology, Norfolk, Virginia. 11. Department of Urology, University of California San Francisco, San Francisco, California. 12. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. 13. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas. 14. Department of Pathology, University of Washington Medical Center, Seattle, Washington. 15. Department of Pathology, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Given the uncertainties inherent in clinical measures of prostate cancer aggressiveness, clinically validated tissue biomarkers are needed. We tested whether Alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) protein levels, measured by immunohistochemistry, and RNA expression, by RNA in situ hybridization (RISH), predict recurrence after radical prostatectomy independent of clinical and pathological parameters. METHODS: AZGP1 IHC and RISH were performed on a large multi-institutional tissue microarray resource including 1,275 men with 5 year median follow-up. The relationship between IHC and RISH expression levels was assessed using the Kappa analysis. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazards models and the Log-rank test. RESULTS: Absent or weak expression of AZGP1 protein was associated with worse recurrence free survival (RFS), disease specific survival, and overall survival after radical prostatectomy in univariable analysis. AZGP1 protein expression, along with pre-operative serum PSA levels, surgical margin status, seminal vesicle invasion, extracapsular extension, and Gleason score predicted RFS on multivariable analysis. Similarly, absent or low AZGP1 RNA expression by RISH predicted worse RFS after prostatectomy in univariable and multivariable analysis. CONCLUSIONS: In our large, rigorously designed validation cohort, loss of AZGP1 expression predicts RFS after radical prostatectomy independent of clinical and pathological variables. Prostate 76:1409-1419, 2016.
BACKGROUND: Given the uncertainties inherent in clinical measures of prostate cancer aggressiveness, clinically validated tissue biomarkers are needed. We tested whether Alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) protein levels, measured by immunohistochemistry, and RNA expression, by RNA in situ hybridization (RISH), predict recurrence after radical prostatectomy independent of clinical and pathological parameters. METHODS:AZGP1 IHC and RISH were performed on a large multi-institutional tissue microarray resource including 1,275 men with 5 year median follow-up. The relationship between IHC and RISH expression levels was assessed using the Kappa analysis. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazards models and the Log-rank test. RESULTS: Absent or weak expression of AZGP1 protein was associated with worse recurrence free survival (RFS), disease specific survival, and overall survival after radical prostatectomy in univariable analysis. AZGP1 protein expression, along with pre-operative serum PSA levels, surgical margin status, seminal vesicle invasion, extracapsular extension, and Gleason score predicted RFS on multivariable analysis. Similarly, absent or low AZGP1 RNA expression by RISH predicted worse RFS after prostatectomy in univariable and multivariable analysis. CONCLUSIONS: In our large, rigorously designed validation cohort, loss of AZGP1 expression predicts RFS after radical prostatectomy independent of clinical and pathological variables. Prostate 76:1409-1419, 2016.
Authors: Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin Journal: Proc Natl Acad Sci U S A Date: 2002-08-16 Impact factor: 11.205
Authors: B Kong; C W Michalski; X Hong; N Valkovskaya; S Rieder; I Abiatari; S Streit; M Erkan; I Esposito; H Friess; J Kleeff Journal: Oncogene Date: 2010-06-28 Impact factor: 9.867
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Aurelien Descazeaud; Alexandre de la Taille; Yves Allory; Hugo Faucon; Laurent Salomon; Tarek Bismar; Robert Kim; Matthias D Hofer; Dominique Chopin; Claude C Abbou; Mark A Rubin Journal: Prostate Date: 2006-07-01 Impact factor: 4.104
Authors: Lisa F Newcomb; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Peter S Nelson; Ian M Thompson; Daniel W Lin Journal: Urology Date: 2009-09-16 Impact factor: 2.649
Authors: Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack Journal: Proc Natl Acad Sci U S A Date: 2004-01-07 Impact factor: 11.205
Authors: Dinesh Singh; Phillip G Febbo; Kenneth Ross; Donald G Jackson; Judith Manola; Christine Ladd; Pablo Tamayo; Andrew A Renshaw; Anthony V D'Amico; Jerome P Richie; Eric S Lander; Massimo Loda; Philip W Kantoff; Todd R Golub; William R Sellers Journal: Cancer Cell Date: 2002-03 Impact factor: 31.743
Authors: Alison Y Zhang; Karen Chiam; Ygal Haupt; Stephen Fox; Simone Birch; Wayne Tilley; Lisa M Butler; Karen Knudsen; Clay Comstock; Krishan Rasiah; Judith Grogan; Kate L Mahon; Tina Bianco-Miotto; Carmela Ricciardelli; Maret Böhm; Susan Henshall; Warick Delprado; Phillip Stricker; Lisa G Horvath; James G Kench Journal: Int J Cancer Date: 2018-12-04 Impact factor: 7.396
Authors: Okyaz Eminaga; Wei Wei; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli; James D Brooks Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: Debashis Sahoo; Wei Wei; Heidi Auman; Antonio Hurtado-Coll; Peter R Carroll; Ladan Fazli; Martin E Gleave; Daniel W Lin; Peter S Nelson; Jeff Simko; Ian M Thompson; Robin J Leach; Dean A Troyer; Lawrence D True; Jesse K McKenney; Ziding Feng; James D Brooks Journal: Oncotarget Date: 2018-01-05
Authors: Mads Dochedahl Winther; Gitte Kristensen; Hein Vincent Stroomberg; Kasper Drimer Berg; Birgitte Grønkær Toft; James D Brooks; Klaus Brasso; Martin Andreas Røder Journal: Diagnostics (Basel) Date: 2020-07-27